Literature DB >> 30140115

Treatment of Parkinson's disease psychosis.

Kevin J Black1.   

Abstract

Early in the course of Parkinson disease (PD), treatment usually goes well. However, after five to ten years, things start to change as treatment requires higher doses of medications and side effects become more problematic. One of the most difficult problems is the development of hallucinations or delusions. Throughout the 20th century, treatment options were unproven and unsatisfactory, but the past 20 years have brought important changes. Two medications that are well tolerated in PD have now proved efficacious in randomized, controlled trials, and others are in development. Here I summarize this history briefly and provide a general plan for treating the patient with PD complicated by psychotic symptoms.

Entities:  

Keywords:  pimavanserin; “Antipsychotic Agents” [Pharmacological Action]; “Delirium”[Mesh]; “Delusions/therapy”[Mesh]; “Hallucinations/therapy”[Mesh]; “Parkinsonian Disorders”[Mesh]

Year:  2018        PMID: 30140115      PMCID: PMC6103448     

Source DB:  PubMed          Journal:  Med Int Rev        ISSN: 0465-5435


  58 in total

1.  Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Authors:  William G Ondo; Ron Tintner; Kevin Dat Voung; Dejian Lai; George Ringholz
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

2.  Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.

Authors:  E Mohr; T Mendis; K Hildebrand; P P De Deyn
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

3.  Remoxipride in the treatment of levodopa-induced psychosis.

Authors:  P Sandor; A E Lang; S Singal; C Angus
Journal:  J Clin Psychopharmacol       Date:  1996-10       Impact factor: 3.153

Review 4.  'Drug holidays' in the treatment of Parkinson's disease. A brief review.

Authors:  J H Friedman
Journal:  Arch Intern Med       Date:  1985-05

Review 5.  Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.

Authors:  Santiago Perez-Lloret; María Cecilia Peralta; Francisco J Barrantes
Journal:  Expert Opin Pharmacother       Date:  2016-11-07       Impact factor: 3.889

6.  A 12-year population-based study of psychosis in Parkinson disease.

Authors:  Elin B Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Christopher G Goetz; Glenn T Stebbins; Dag Aarsland; Guido Alves
Journal:  Arch Neurol       Date:  2010-08

7.  Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis.

Authors:  A E Lang; P Sandor; J Duff
Journal:  Clin Neuropharmacol       Date:  1995-02       Impact factor: 1.592

8.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

9.  Olanzapine treatment for dopaminergic-induced hallucinations.

Authors:  William G Ondo; Joel K Levy; Kevin Dat Vuong; Christine Hunter; Joseph Jankovic
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

10.  A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

Authors:  Paul Shotbolt; Michael Samuel; Chris Fox; Anthony S David
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

View more
  1 in total

1.  A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease.

Authors:  John R Younce; Albert A Davis; Kevin J Black
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.